A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

277

Participants

Timeline

Start Date

July 6, 2020

Primary Completion Date

June 4, 2021

Study Completion Date

January 18, 2022

Conditions
Eosinophilic Esophagitis
Interventions
OTHER

Placebo

Placebo

DRUG

lirentelimab (AK002)

Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.

Trial Locations (78)

3128

Allakos Investigational Site, Box Hill

3181

Allakos Investigational Site, Prahran

5000

Allakos Investigational Site, Adelaide

5112

Allakos Investigational Site, Elizabeth Vale

10029

Allakos Investigational Site, New York

11021

Allakos Investigational Site, Great Neck

17822

Allakos Investigational Site, Danville

19104

Allakos Investigational Site, Philadelphia

20176

Allakos Investigational Site, Leesburg

20815

Allakos Investigational Site, Chevy Chase

27262

Allakos Investigational Site, High Point

27599

Allakos Investigational Site, Chapel Hill

27710

Allakos Investigational Site, Durham

27804

Allakos Investigational Site, Rocky Mount

28210

Allakos Investigational Site, Charlotte

28277

Allakos Investigational Site, Charlotte

28801

Allakos Investigational Site, Asheville

29615

Allakos Investigational Site, Greenville

30342

Allakos Investigational Site, Atlanta

31904

Allakos Investigational Site, Columbus

32132

Allakos Investigational Site, Edgewater

32256

Allakos Investigational Site, Jacksonville

32803

Allakos Investigational Site, Orlando

32806

Allakos Investigational Site, Orlando

33176

Allakos Investigational Site, Miami

33511

Allakos Investigational Site, Brandon

33603

Allakos Investigational Site, Tampa

33615

Allakos Investigational Site, Tampa

35209

Allakos Investigational Site, Birmingham

37212

Allakos Investigational Site, Nashville

37343

Allakos Investigational Site, Hixson

37421

Allakos Investigational Site, Chattanooga

38801

Allakos Investigational Site, Huntsville

40503

Allakos Investigational Site, Lexington

44060

Allakos Investigational Site, Mentor

44106

Allakos Investigational Site, Cleveland

44302

Allakos Investigational Site, Akron

45229

Allakos Investigational Site, Cincinnati

45231

Allakos Investigational Site, Cincinnati

45415

Allakos Investigational Site, Dayton

46202

Allakos Investigational Site, Indianapolis

48098

Allakos Investigational Site, Troy

48109

Allakos Investigational Site, Ann Arbor

52242

Allakos Investigational Site, Iowa City

59901

Allakos Investigational Site, Kalispell

60611

Allakos Investigational Site, Chicago

64108

Allakos Investigational Site, Kansas City

70526

Allakos Investigational Site, Crowley

72205

Allakos Investigational Site, Little Rock

73112

Allakos Investigational Site, Oklahoma City

75044

Allakos Investigational Site, Garland

78229

Allakos Investigational Site, San Antonio

78704

Allakos Investigational Site, Austin

80045

Allakos Investigational Site, Aurora

80112

Allakos Investigational Site, Centennial

84065

Allakos Investigational Site, Riverton

84092

Allakos Investigational Site, Sandy City

84132

Allakos Investigational Site, Salt Lake City

84405

Allakos Investigational Site, Ogden

85016

Allakos Investigational Site, Phoenix

85021

Allakos Investigational Site, Phoenix

85234

Allakos Investigational Site, Gilbert

85251

Allakos Investigational Site, Scottsdale

89106

Allakos Investigational Site, Las Vegas

89511

Allakos Investigational Site, Reno

90025

Allakos Investigational Site, Los Angeles

90404

Allakos Investigational Site, Santa Monica

92037

Allakos Investigational Site, La Jolla

92780

Allakos Investigational Site, Tustin

93003

Allakos Investigational Site, Ventura

94598

Allakos Investigational Site, Walnut Creek

94612

Allakos Investigational Site, Oakland

98105

Allakos Investigational Site, Seattle

98115

Allakos Investigational Site, Seattle

02111

Allakos Investigational Site, Boston

02115

Allakos Investigational Site, Boston

02215

Allakos Investigational Site, Boston

1105 AZ

Allakos Investigational Site, Amsterdam

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allakos Inc.

INDUSTRY

NCT04322708 - A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis | Biotech Hunter | Biotech Hunter